KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Revenue (2016 - 2026)

Neogenomics filings provide 17 years of Revenue readings, the most recent being $186.7 million for Q1 2026.

  • On a quarterly basis, Revenue rose 11.09% to $186.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $746.0 million, a 10.95% increase, with the full-year FY2025 number at $727.3 million, up 10.11% from a year prior.
  • Revenue hit $186.7 million in Q1 2026 for Neogenomics, down from $190.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $190.2 million in Q4 2025 to a low of $117.2 million in Q1 2022.
  • Median Revenue over the past 5 years was $156.2 million (2024), compared with a mean of $157.4 million.
  • Biggest five-year swings in Revenue: grew 1.42% in 2022 and later grew 17.99% in 2023.
  • Neogenomics' Revenue stood at $138.7 million in 2022, then increased by 12.15% to $155.6 million in 2023, then rose by 10.57% to $172.0 million in 2024, then rose by 10.56% to $190.2 million in 2025, then fell by 1.84% to $186.7 million in 2026.
  • The last three reported values for Revenue were $186.7 million (Q1 2026), $190.2 million (Q4 2025), and $187.8 million (Q3 2025) per Business Quant data.